Nicardipine HCl
产品说明书
 |
同义名 : | YC-93; Nicardipine (hydrochloride); RS 69216; Nicardipine hydrochloride |
| CAS号 : | 54527-84-3 | |
| 货号 : | A570738 | |
| 分子式 : | C26H30ClN3O6 | |
| 纯度 : | 99% | |
| 分子量 : | 515.99 | |
| MDL号 : | MFCD00057327 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Nicardipine hydrochloride (NC-HCl), a calcium channel blocker for the treatment of chronic stable angina and hypertension, seems to be a potential therapeutic transdermal system candidate, mainly due to its low dose, short half-life, and high first-pass metabolism[3]. Uterine activity was inhibited by all treatment regimens, but the most significant inhibition was achieved by the higher dose of nicardipine, which nearly abolished all uterine activity in pregnant rabbit during induced preterm uterine contractions[4]. The L-type voltage-dependent Ca(2+) channels (L-VDCC) blocker, nicardipine, significantly inhibited ACh- (acetylcholine) and Ca(2+)-enhanced BSM (bronchial smooth muscles) contractions in guinea pigs infused with HCl[5]. In patients with moyamoya disease, nicardipine may have a beneficial effect on cerebral hemodynamics and may prevent ischemic sequelae by optimizing existing collateral circulation[6]. In rabbit, nicardipine-HCl decreased the spontaneous rate of the sinoatrial (SA) node and prolonged sinus recovery time, dose-dependently. The effective refractory period (ERP) and functional refractory period (FRP) of the atrioventricular (AV) node and AV conduction time (A-H interval) were also prolonged by nicardipine-HCl in a dose-dependent manner[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02286089 | Age-related Macular Degenerati... 展开 >>on 收起 << | Phase 1 Phase 2 | Recruiting | December 2019 | United States, California ... 展开 >> Retina Vitreous Associates Medical Group Recruiting Los Angeles, California, United States, 900211 Contact: Janet Kurokouchi, B.Sc. 310-289-2478 ext 1243 JKurokouchi@laretina.com Contact: Gerard Aquino, B.Sc. 310-289-2478 ext 1225 GAquino@laretina.com Principal Investigator: David Boyer, MD Byers Eye Institute, Stanford School of Medicine Recruiting Palo Alto, California, United States, 94303 Contact: Lisa Greer, MBA 650-725-9184 lgreer7@stanford.edu Principal Investigator: Diana Do, Prof. Retinal Consultants Medical Group Recruiting Sacramento, California, United States, 95819 Contact: Erin Nickerman 916-453-5429 nickermane@retinalMD.com Contact: Whitney Lewis 916-453-5429 lewisw@retinalmd.com Principal Investigator: David Telander, MD West Coast Retina Medical Group, Inc Recruiting San Francisco, California, United States, 94109 Contact: Kaitlin E. Miani, BA 415-972-4607 kmiani@westcoastretina.com Contact: C. Principal Investigator: Richard McDonald, MD Israel Hadassah Ein Kerem University Hospital Recruiting Jerusalem, Israel, 91120 Contact: Devora Marks Ohana 972-2-6776324 dryamdstudy@gmail.com Principal Investigator: Tareq Jaouni, MD Rabin Medical Center Recruiting Petah Tikva, Israel Contact: Vivi Dagan 972-3-9377199 eyeclinic@clalit.org.il Principal Investigator: Rita Ehrlich, MD Kaplan Medical Center Recruiting Rehovot, Israel Contact: Michal Scwartzberg 972-8-9441691 kaplaneye1@gmail.com Principal Investigator: Haia Morori-Katz, MD Tel Aviv Souraski Medical Center Recruiting Tel Aviv, Israel, 91121 Contact: Sagit Bechor 03-6974361 sagitba@tlvmc.gov.il Principal Investigator: Adiel Barak, MD, Prof. 收起 << |
| NCT02725840 | - | Recruiting | April 2021 | United States, Florida ... 展开 >> Department of Radiation Oncology Davis Cancer Pavilion Recruiting Gainesville, Florida, United States, 32611 Contact: John M Lybarger, MPH 352-265-0680 ext 87829 lybarj@shands.ufl.edu Principal Investigator: Walter O'Dell, PhD Sub-Investigator: Karen Daily, DO Sub-Investigator: Coy Heldermon, MD, PhD Sub-Investigator: David Wymer, MD Sub-Investigator: Fei Zou, PhD Sub-Investigator: Paul Okunieff, MD Sub-Investigator: Jorge Lascano, MD University of Florida Health Proton Therapy Institute Recruiting Jacksonville, Florida, United States, 32206 Contact: Julie Bradley, MD 904-588-1800 jbradley@floridaproton.org Sub-Investigator: Nancy Mendenhall, MD Sub-Investigator: Christopher Klassen, MD, PhD Sub-Investigator: Michael Rutenberg, MD Sub-Investigator: Roi Dagan, MD, MS Principal Investigator: Julie Bradley 收起 << | |
| NCT01893307 | Head And Neck Cancer | Phase 2 Phase 3 | Recruiting | August 2023 | United States, Arizona ... 展开 >> Mayo Clinic - Arizona Recruiting Scottsdale, Arizona, United States, 85259 United States, California University of California at San Diego Recruiting La Jolla, California, United States, 92093 Contact: Loren Mell, MD United States, Florida Florida Health Protocol Institute Recruiting West Palm Beach, Florida, United States, 33407 Contact: Roi Dagan, MD United States, Illinois Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States, 60611 Contact: John H. Han-Chang, MD United States, Maryland University of Maryland Recruiting College Park, Maryland, United States, 20742 Contact: William Regine, MD Contact: Charles Simone, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Paul Busse, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Robert Foote, MD United States, New York Memorial-Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Nancy Y. Lee, MD United States, Pennsylvania University of Pennsylvania Health System Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Alexander Lin, MD United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 United States, Washington University of Washington Recruiting Seattle, Washington, United States, 98105 Contact: Upendra Parvathaneni, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.69mL 1.94mL 0.97mL |
19.38mL 3.88mL 1.94mL |
| 参考文献 |
|---|